NYSEAMERICAN:HEB Hemispherx BioPharma (HEB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Hemispherx BioPharma Stock (NYSEAMERICAN:HEB) 30 days 90 days 365 days Advanced Chart Get Hemispherx BioPharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.09▼$0.2252-Week Range N/AVolume2.31 million shsAverage Volume102,599 shsMarket Capitalization$232,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewHemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.Read More… Receive HEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemispherx BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HEB Stock News HeadlinesHamilton ETFs Launches Hamilton Canadian Financials Index ETFJanuary 20, 2025 | businesswire.comH-E-B’s affordable grocery chain Joe V’s Smart Shop is coming to IrvingAugust 11, 2024 | dallasnews.comBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.May 4, 2025 | Golden Portfolio (Ad)Hemispherx Biopharma earnings preview: what Wall Street is expectingMay 15, 2024 | markets.businessinsider.comH-E-B hosting hiring fairsJanuary 7, 2024 | cbsnews.comH-E-B bets on loyal customers as it expands affordable Joe V’s storesOctober 3, 2023 | chron.comH-E-B enters the film world with a five-part docuseries covering Texas parks and wildlifeAugust 28, 2023 | chron.comH-E-B opens doors to new Georgetown grocery storeJuly 1, 2023 | bizjournals.comSee More Headlines HEB Stock Analysis - Frequently Asked Questions How were Hemispherx BioPharma's earnings last quarter? Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) released its quarterly earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share for the quarter, beating analysts' consensus estimates of ($1.70) by $0.63. The specialty pharmaceutical company had revenue of $0.03 million for the quarter. When did Hemispherx BioPharma's stock split? Shares of Hemispherx BioPharma reverse split before market open on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Hemispherx BioPharma? Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hemispherx BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Goodrich Petroleum (GDPMQ), Biocept (BIOC), CTI BioPharma (CTIC), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN) and Ayala Pharmaceuticals (ADXS). Company Calendar Last Earnings8/15/2019Today5/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:HEB Previous SymbolNYSE:HEB CIK946644 Webwww.hemispherx.net Phone+1-407-2718516FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares2,442,000Free FloatN/AMarket Cap$232,000.00 OptionableNot Optionable BetaN/A 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NYSEAMERICAN:HEB) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemispherx BioPharma, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemispherx BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.